Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Pardali (Gothenburg, Sweden), F. Jiang (Gothenburg, Sweden), M. Fitzgerald (Boston, United States of America), G. Matschiner (Boston, United States of America), D. Keeling (Gothenburg, Sweden). AZD1402/PRS-060, an inhaled Anticalin® IL-4Ra antagonist, potently inhibits IL-4 induced functional effects in human whole blood, which can be employed translationally in clinical studies.. 5248

Member's Comments

No comment yet.

Related content which might interest you: Importin-7 knockdown reduces corticosteroid induced glucocorticoid receptor nuclear localisation and suppression of IL-1beta induced CXCL8 Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 A novel receptor antagonist, c-027, inhibits airway contraction in human and murine models of allergen, independent of inflammatory mediator release Source: Annual Congress 2009 - Novel mechanisms in the pathogenesis of asthma Year: 2009 Liver-X-receptor agonists, but not dexamethasone, inhibit leukotriene production from human white blood cells pretreated with GM-CSF and activated with fMLP Source: Annual Congress 2007 - New treatments for asthma and COPD - experimental evidence Year: 2007 The pro-apoptotic effect of cysteinyl leukotriene receptor (CysLT-R) antagonist montelukast is mediated by CysLT-Rs expression on antigen-stimulated T cells Source: Eur Respir J 2003; 22: Suppl. 45, 100s Year: 2003 Dexamethasone inhibits LPS-induced expression of human β-defensin-2 via down-regulation of TLR4 Source: Eur Respir J 2003; 22: Suppl. 45, 562s Year: 2003 Comparison of transcriptional differences between IL-4Ra and IL-5 blockade in a mouse model of asthma Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Endothelin receptor B (ETBR) dependent GM-CSF mRNA stabilization explains the higher efficacy of bosentan vs. ambrisentan in the reduction of GM-CSF release from human airway smooth muscle cells (HASMCs) Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011 Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma. Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019 Serotonin (5-hydroxytryptamine) modulates cytokine and chemokine production in lipopolysaccharide-primed human monocytes via stimulation of different 5-HT receptor subtypes Source: Annual Congress 2005 - Inflammation and remodelling in allergy and asthma Year: 2005 Cilomilast, a second generation phosphodiestease 4 inhibitor, in combination with PGE2 attenuates fMLP, IL-8 and cigarette smoke-induced effects on the mechanical and functional properties of neutrophils Source: Eur Respir J 2001; 18: Suppl. 33, 161s Year: 2001 EP4 agonist increases myeloid derived suppressor cells activity and reduces airway inflammatory events in a murine model of asthma Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020 The dissociated steroid receptor ligand from plant origin called compound A (CpdA) inhibits the production of steroid-resistant chemokines induced by TNFα/IFNγ in airway smooth muscle (ASM) cells in both asthma and healthy subjects Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012 Interleukin-17 enhances epithelial IL-6 production solely by stabilizing IL-6 mRNA, which is reversed by microRNA16 Source: Eur Respir J 2007; 30: Suppl. 51, 212s Year: 2007 The expression of interleukin-13 gene is regulated by nfat1 in human T cells Source: Annual Congress 2005 - Regulation of the allergic and asthmatic response Year: 2005 Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-α release from human alveolar macrophages Source: Eur Respir J 2007; 29: 986-994 Year: 2007 Protease activated receptor 2 (PAR2) antagonism reduces pro-inflammatory cytokine production in bronchial epithelial cells Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020 dsRNA enhances eotaxin-3 production through interleukin-4 receptor upregulation in airway epithelial cells Source: Eur Respir J 2005; 26: 795-803 Year: 2005 The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001 Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Endothelin receptor antagonists (ERAs) neutralize LPS-induced cytokine release from pulmonary vascular smooth muscle cells (PVSMCs) by down-regulation of CD14 Source: Annual Congress 2013 –Airway smooth muscle and cell biology Year: 2013